Last reviewed · How we verify
Placebo for Upadacitinib
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trials for upadacitinib indications (e.g., rheumatoid arthritis, atopic dermatitis, ulcerative colitis).
At a glance
| Generic name | Placebo for Upadacitinib |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (upadacitinib, a JAK inhibitor) by comparison. Any observed effects in the placebo arm are attributed to natural disease progression, regression to the mean, or the placebo effect itself. This Phase 3 placebo arm allows researchers to isolate the true therapeutic benefit of upadacitinib.
Approved indications
- Control arm in Phase 3 clinical trials for upadacitinib indications (e.g., rheumatoid arthritis, atopic dermatitis, ulcerative colitis)
Common side effects
- Adverse events in placebo arm reflect natural disease progression and non-specific effects
Key clinical trials
- Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study. (PHASE2)
- Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (PHASE3)
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (PHASE3)
- A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (PHASE3)
- Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Upadacitinib CI brief — competitive landscape report
- Placebo for Upadacitinib updates RSS · CI watch RSS
- AbbVie portfolio CI